• Français

CHU Sainte-Justine
Thursday, February 2 2023

Taking HIV research further

Montreal Scientists Unveil Important Advance

MONTREAL, February 2, 2023 – Research teams from the Montreal Clinical Research Institute (IRCM) and the CHU Sainte-Justine unveiled a promising advance that will help optimize the search for solutions to HIV.

Published today in the Stem Cell Report journal, this work resulting from a collaboration between Dr. Elie Haddad (MD / Ph.D.), clinical researcher at CHU Sainte-Justine and Dr. Éric Cohen (Ph.D), Director of the Human Retrovirology Unit at the IRCM, presents a new efficient and accessible preclinical model that will facilitate research work on HIV.

The study of a virus such as HIV requires understanding the pathogen’s specific modes of transmission, how it infects cells and how it persists despite the host’s immune responses and highly effective antiretroviral treatments. This is the work that scientists around the world have undertaken for several decades in order to counter and treat HIV. To make it possible, in vivo lab models require the use of human stem cells and fetal tissues - like the thymus- to model the infection and the viral multiplication, the persistence of HIV despite treatments, as well as the deleterious effects of the virus on bodily functions. It should also be emphasized that many of these questions cannot be fully investigated in vitro and require in vivo models that reproduce the HIV infection and disease as closely as observed in humans.

An Innovative Model

The innovative preclinical model proposed in this article (named CCST, because it is developed from cord blood and thymus collected during heart surgery) allows the recreation of a physiological and immune environment comparable to that found in humans during HIV infection. This new model has proven to be just as effective as existing models, without requiring the use of fetal tissue, as previously.

The CCST model recreates the conditions of real infections and a robust immune response, including the increased presence of T cells and their functions as usually observed in the presence of HIV in humans. Scientists were able to document the presence of silent forms of HIV in the cells event in cases of undetectable viral load following antiretroviral administration. They also observed viral resurgence after cessation of treatment, suggesting that HIV reservoirs remain latent in these laboratory models, as observed in humans.

“This approach is extremely interesting because it is accessible to research teams around the world, explains Dr. Elie Haddad. It opens up a lot of research possibilities, especially in terms of finding HIV reservoirs, which is imperative to achieve a complete cure for HIV. "

While the availability of needed biological material is an important factor in favour of the CCST approach, other elements contribute to the enthusiasm CCST generates for HIV research. In addition to being available in quantity, and easily retrievable by surgery, the biological samples it requires can also easily be stored in biobanks or by cryopreservation until needed. This is a great improvement in terms of access, feasibility and flexibility for those studying HIV infection and developing therapeutic options.

“HIV remains a major threat to humans because patients needed lifetime medication to survive," said Dr. Eric Cohen. That is why we must continue the global search for a cure. Important advances and new study designs such as the one we are proposing are an important step in this direction.”

HIV, an Ongoing Threat

Until the end of the last century, the spectre of HIV was terrifying to the public as it implied a painful and certain death. Then, the arrival of antiretroviral drugs made it possible for people with HIV to lead relatively normal lives without transmitting the disease, thanks to an undetectable viral load.

However, the effectiveness of these treatments often depends on early diagnosis and their interruption leads to a rapid development of the disease. In addition, for many people around the world, especially those living in developing countries, these treatments remain more or less accessible. Finally, although current antiretroviral treatments are effective in preventing the progression of the infection and its transmission, these treatments are not curative.

Today, reports from the World Health Organization (WHO) reveal that progress made to counter HIV are faltering. In 2019, the WHO Global Health Observatory estimated that 38 million people worldwide were living with HIV. In Canada, in 2018, Health Canada estimated that an average of 62,050 people across the country were living with HIV, and that 1 in 8 Canadians with HIV was undiagnosed and unaware of their illness. 

These findings underscore the importance of this work, which is the result of a successful collaboration between two leading research centres.


This work was supported by grants from the Canadian Institutes of Health Research (CIHR) and the Canadian Consortium for HIV Cure Research (CanCure). Dr. Haddad also holds the Bank of Montreal Research Chair in Pediatric Immunology, Sainte-Justine UHC Foundation.

About the IRCM

The Montreal Clinical Research Institute (IRCM) is renowned biomedical research institute located in the heart of Montreal. Founded in 1967, the IRCM was the first research centre in Quebec to bring basic researchers and clinicians together under one roof, to counter some of the most serious and disabling diseases. A unique model at the time, the IRCM is now one of the most successful research and clinical centres in the country.

About the study

The article « Generation of Functional Human T Cell Development in NOD/SCID/IL2rγnull Humanized Mice Without Using Fetal Tissue: Application as a Model of HIV Infection and Persistence » by C. Colas, O. Volodina, K. Béland, T. N.Q. Pham, Y. Li, F. Dallaire, C. Soulard, W. Lemieux, A. B.L. Colamartino, C. Tremblay-Laganière, R. Dicaire, J. Guimond, S. Vobecky, N. Poirier, N. Patey, É. A. Cohen et Elie Haddad, was published February 2, 2023 in Stem Cell Reports. Funding for the study was provided by the Canadian Institutes of Health Research (CIHR) and the The Canadian HIV Cure Enterprise (CanCURE).


The CHU Sainte-Justine Research Centre is a leading mother-child research institution affiliated with the Université de Montréal. It brings together 280 research investigators, including over 140 clinician-scientists, as well as more than 550 graduate and postgraduate students focused on finding innovative prevention means, faster and less invasive treatments, as well as personalized approaches to medicine. The centre is an integral part of CHU Sainte-Justine, which is the largest mother-child centre in Canada

CHU Sainte-Justine

CHU Sainte-Justine Research Centre

For information

Media Contact :
Justine Mondoux-Turcotte 
Advisor - Media Relations and External Relations
CHU Sainte-Justine
514 345-7707


Persons mentioned in the text
About this page
Updated on 2/2/2023
Created on 2/2/2023
Alert or send a suggestion

Grow Beyond our wildest dreams

With the support of donors like you, at the heart of the Grow Beyond campaign, we are leading healthcare teams towards the opportunities offered by science and new technologies, so that every child, no matter where in Quebec, has access to the unique expertise and know-how of CHU Sainte-Justine. Together, let's join forces for their future.

Grow Beyond with us.

Contact Us

514 345-4931


© 2006-2014 CHU Sainte-Justine.
All rights reserved. 
Terms of Use,  Confidentiality,  Security


All information contained within the CHU Sainte-Justine site should not be used as a substitute for the advice of a duly qualified and authorized medical practitioner or any other health professional. The information provided on this site is intended for educational and informational purposes only.

Consult your physician if you feel ill or call 911 for any medical emergency.

CHU Sainte-Justine